Managing adverse effects of glaucoma medications

Kenji Inoue, Kenji Inoue

Abstract

Glaucoma is a chronic, progressive disease in which retinal ganglion cells disappear and subsequent, gradual reductions in the visual field ensues. Glaucoma eye drops have hypotensive effects and like all other medications are associated with adverse effects. Adverse reactions may either result from the main agent or from preservatives used in the drug vehicle. The preservative benzalkonium chloride, is one such compound that causes frequent adverse reactions such as superficial punctate keratitis, corneal erosion, conjunctival allergy, and conjunctival injection. Adverse reactions related to main hypotensive agents have been divided into those affecting the eye and those affecting the entire body. In particular, β-blockers frequently cause systematic adverse reactions, including bradycardia, decrease in blood pressure, irregular pulse and asthma attacks. Prostaglandin analogs have distinctive local adverse reactions, including eyelash bristling/lengthening, eyelid pigmentation, iris pigmentation, and upper eyelid deepening. No systemic adverse reactions have been linked to prostaglandin analog eye drop usage. These adverse reactions may be minimized when they are detected early and prevented by reducing the number of different eye drops used (via fixed combination eye drops), reducing the number of times eye drops are administered, using benzalkonium chloride-free eye drops, using lower concentration eye drops, and providing proper drop instillation training. Additionally, a one-time topical medication can be given to patients to allow observation of any adverse reactions, thereafter the preparation of a topical medication with the fewest known adverse reactions can be prescribed. This does require precise patient monitoring and inquiries about patient symptoms following medication use.

Keywords: adverse reactions; glaucoma eye drops; main agent; preservatives.

Figures

Figure 1
Figure 1
Combinations of glaucoma medications.
Figure 2
Figure 2
Eyelash lengthening/bristling with bimatoprost administration. Note: Reprinted from Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye. 2012;26(11):1465–1472.
Figure 3
Figure 3
Eyelid pigmentation following bimatoprost administration. Note: Reprinted from Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye. 2012;26(11):1465–1472.
Figure 4
Figure 4
Iris pigmentation before and 6 months after latanoprost therapy. Note: Reprinted with permission from Inoue K, Wakakura M, Inoue J, et al. [Adverse reaction after use of latanoprost in Japanese glaucoma patients]. Nihon Ganka Gakkai Zasshi. 2006;110(8):581–587. Copyright © 2006 Japanese Ophthalmological Society.
Figure 5
Figure 5
Deepening of the upper eyelid sulcus in a patient treated with travoprost in the left eye.

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
    1. Resnikoff S, Keys TU. Future trends in global blindness. Indian J Ophthalmol. 2012;60(5):387–395.
    1. Yamada M, Hiratsuka Y, Roberts CB, et al. 2010, Prevalence of visual impairment in adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol. 2010;17(1):50–57.
    1. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculapathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36(1):182–191.
    1. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641–1648.
    1. Collaborative Normal-Tension Glaucoma Study-Group The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126(4):498–505.
    1. The AGIS Investigators The Advanced glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2008;130(4):429–440.
    1. Quaranta L, Katsanos A, Russo A, Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58(1):26–41.
    1. Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2008;49(10):4226–4231.
    1. Quaranta L, Miglior S, Floriani I, Pizzolante T, Konstas AGP. Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917–2923.
    1. Rosin LM, Bell NP. Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops. Clin Ophthalmol. 2013;7:2131–2135.
    1. Noecker R, Miller KV. Benzalkonium chrolide in glaucoma medications. Ocul Surf. 2011;9(3):159–162.
    1. Boudouin C. Detrimental effect of preservatives in eye drops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–726.
    1. Miyake K, Ota I, Ibaraki N, et al. Enchanced disruption of the blood-aqueous barrier and the indence of angiographic cystoid macula edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol. 2001;119(3):387–394.
    1. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12(6):480–485.
    1. Janczewski P, Boulanger C, Iqbal A, Vanhoutte PM. Endothelium-dependent effects of carteolol. J Pharmacol Exp Ther. 1988;247(2):590–595.
    1. Chauhan JK, Mishra YC, Knilnani K. A clinical study of effect of oral atenolol on normal intraocular pressure and systemic blood pressure. Indian J Ophthalmol. 1989;37(4):179–181.
    1. Schoene RB, Auban T, Ward RL, Beasley BC. Effects of tropical, betaxolol, timolol, and bronchitis. Am J Ophthalmol. 1984;97(1):86–92.
    1. Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye. 2012;26(11):1465–1472.
    1. Inoue K, Wakakura M, Inoue J, et al. Adverse reaction after use of latanoprost in Japanese glaucoma patients. Nihon Ganka Gakkai Zasshi. 2006;110(8):581–587. Japanese.
    1. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22(8):626–631.
    1. Honrubia F, García-Sánchez J, Polo V, de la Casa JM, Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: meta-analysis of randomized clinical trials. Br J Ophthalmol. 2009;93(3):316–321.
    1. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs. A meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17(8):667–673.
    1. Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–456.
    1. Crichton AC, Vold S, Williams JM, Hollander DA. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension. Adv Ther. 2013;30(3):260–270.
    1. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997;124(4):554–547.
    1. Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology. 2010;117(5):1024–1031.
    1. Giannico AT, Lima L, Russ HH, Montiani-Ferreira F. Eyelash growth included by topical prostaglandin analogues, bimatoprost, travoprost, travoprost and latanoprost in rabbits. J Ocular Pharmacol Ther. 2013;29(9):817–820.
    1. Priluck JC, Fu S. Latisse-included periocular skin hyperpigmentation. Arch Ophthalmol. 2010;128(6):792–793.
    1. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 1996;103(11):1916–1924.
    1. Watson PG, the Latanoprost Study Group Latanoprost: Two years’ experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105(1):82–87.
    1. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81(8):574–577.
    1. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55(1):22–27.
    1. Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8(5):e61638.
    1. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol. 1999;127(5):602–604.
    1. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakius. Arch Ophthalmol. 1999;117(1):34–40.
    1. Litcher PR, Newman LP, Wheeler NC, Beall OV. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol. 1978;85(4):495–502.
    1. Strahlman E, Tipping R, Voqel R. International Dorzolamide Study Group: A double-masked, randomized 1-year study comparing dorzolamide (Trusport), timolol, and betaxolol. Arch Ophthalmol. 1995;113(8):1009–1016.
    1. Silver LH. Brizolamide Comfort Study Group: Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results for two multicenter comfort studies. Surv Ophthalmol. 2000;44:S141–S145.
    1. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127(4):403–406.
    1. Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89(1):76–80.
    1. Oshika T, Araie M, Sugiyama T, Nakagina M, Azuma I. Effect of bunazosin hydrochloride on intraocular pressure and aqueous humor dymanics in normotensive human eyes. Arch Ophthalmol. 1991;109(11):1569–1574.
    1. Azuma I, Kitazawa Y, Tsukahara S, Takase M, Shiose Y, Komemushi S. Optimal concentration-finding study of bunazosin hydrochloride ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Atarashii Ganka (Journal of the Eye) 1994;11(3):423–429. Japanese.
    1. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol. 1975;80(3):379–388.
    1. Fiore PM, Jacobs IH, Goldberg DB. Drug-induced pemphigoid. A spectrum of diseases. Arch Ophthalmol. 1987;105(12):1660–1663.
    1. Anderson JA. Systemic absorption of topical ocularly applied epinephrine and dipivefrin. Arch Ophthalmol. 1980;98(2):350–353.
    1. Toris CB, Tafoya ME, Camras CB, Yablonski ME. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102(3):456–461.
    1. Butler P, Mannschreck M, Lin S, Hwang I, Alvaeado J. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol. 1995;113(3):293–296.
    1. Abrams DA, Robin AL, Polack IP, de Faller JM, DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol. 1987;105(9):1205–1207.
    1. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22(1):5–18.
    1. Quaranta L, Biagiolo E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389.
    1. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327–335.
    1. Inoue K, et al. Ocular hypotensive effects and safety of latanoprost without benzalkonium hydrochloride. Atarashii Ganka (Journal of the Eye) 2011;28(11):1635–1639. Japanese.
    1. Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57(2):179–184.
    1. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102(4):551–553.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner